Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125403321 | 12540332 | 1 | I | 20160701 | 0 | 20160707 | 20160707 | DIR | 58.00 | YR | M | N | 74.60000 | KG | 20160706 | N | OT | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125403321 | 12540332 | 1 | PS | ABRAXANE | PACLITAXEL | 1 | Intravenous (not otherwise specified) | 15P1238 | 0 | ||||||||||
| 125403321 | 12540332 | 2 | SS | LEUCOVORIN. | LEUCOVORIN | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125403321 | 12540332 | 4 | C | INSULIN ASPART | INSULIN ASPART | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 6 | C | INSULIN DETEMIR | INSULIN DETEMIR | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 8 | C | INSULIN GLARGINE | INSULIN GLARGINE | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 10 | C | INSULIN GLULISINE | INSULIN GLULISINE | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 12 | C | INSULIN LISPRO | INSULIN LISPRO | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 14 | C | TYLENOL | ACETAMINOPHEN | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 16 | C | LOVENOX | ENOXAPARIN SODIUM | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 18 | C | FENTANYL TRANSDERMAL SYSTEM | FENTANYL | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 20 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 22 | C | MORPHINE SULFATE. | MORPHINE SULFATE | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 24 | C | ZOFRAN | ONDANSETRON HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125403321 | 12540332 | 25 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125403321 | 12540332 | 26 | SS | 5-FU | FLUOROURACIL | 1 | Intravenous (not otherwise specified) | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125403321 | 12540332 | 1 | Pancreatic carcinoma |
| 125403321 | 12540332 | 2 | Pancreatic carcinoma |
| 125403321 | 12540332 | 25 | Pancreatic carcinoma |
| 125403321 | 12540332 | 26 | Pancreatic carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125403321 | 12540332 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125403321 | 12540332 | Dehydration | |
| 125403321 | 12540332 | Hyperglycaemia | |
| 125403321 | 12540332 | Nausea | |
| 125403321 | 12540332 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 125403321 | 12540332 | HP |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125403321 | 12540332 | 1 | 20160617 | 0 | ||
| 125403321 | 12540332 | 2 | 20160617 | 0 | ||
| 125403321 | 12540332 | 25 | 20160617 | 0 | ||
| 125403321 | 12540332 | 26 | 20160617 | 0 |